-
公开(公告)号：US09447058B2
公开(公告)日：2016-09-20
申请号：US14878749
申请日：2015-10-08
Applicant: Duke University , Chaperone Therapeutics, Inc.
Inventor： Dennis J. Thiele , Daniel W. Neef , Jose S. Mendoza
IPC: C07D277/42 , A61K31/415 , A61K31/4155 , A61K31/426 , A61K45/06 , C07D231/40 , C07D277/60 , C07D409/04 , C07K14/47 , C07C211/01 , C07D231/38 , C07D277/38 , C07D405/14 , C07D413/12
CPC classification number: C07D231/40 , A61K31/415 , A61K31/4155 , A61K31/426 , A61K45/06 , C07C211/01 , C07C211/29 , C07D231/38 , C07D277/38 , C07D277/42 , C07D277/46 , C07D277/60 , C07D405/14 , C07D409/04 , C07D413/12 , C07K14/47 , A61K2300/00
Abstract: The present invention relates to 1,3-thiazole compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof.
-
公开(公告)号：US20160024035A1
公开(公告)日：2016-01-28
申请号：US14878749
申请日：2015-10-08
Applicant: Duke University , Chaperone Therapeutics, Inc.
Inventor： Dennis J. Thiele , Daniel W. Neef , Jose S. Mendoza
IPC: C07D277/42
CPC classification number: C07D231/40 , A61K31/415 , A61K31/4155 , A61K31/426 , A61K45/06 , C07C211/01 , C07C211/29 , C07D231/38 , C07D277/38 , C07D277/42 , C07D277/46 , C07D277/60 , C07D405/14 , C07D409/04 , C07D413/12 , C07K14/47 , A61K2300/00
Abstract: The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.
-
公开(公告)号：US09718784B2
公开(公告)日：2017-08-01
申请号：US15131938
申请日：2016-04-18
Applicant: DUKE UNIVERSITY , CHAPERONE THERAPEUTICS, INC
Inventor： Dennis J. Thiele , Daniel W. Neef , Jose Serafin Mendoza
IPC: C07D231/38 , C07D231/40 , A61K31/415 , A61K31/4155 , A61K31/426 , A61K45/06 , C07D277/42 , C07D277/60 , C07D409/04 , C07K14/47 , C07C211/01 , C07D277/38 , C07D405/14 , C07D413/12 , C07C211/29 , C07D277/46
CPC classification number: C07D231/40 , A61K31/415 , A61K31/4155 , A61K31/426 , A61K45/06 , C07C211/01 , C07C211/29 , C07D231/38 , C07D277/38 , C07D277/42 , C07D277/46 , C07D277/60 , C07D405/14 , C07D409/04 , C07D413/12 , C07K14/47 , A61K2300/00
Abstract: The present invention relates to substituted pyrazole compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof) and pharmaceutical formulations thereof.
-
公开(公告)号：US09717709B2
公开(公告)日：2017-08-01
申请号：US15269584
申请日：2016-09-19
Applicant: Duke University , Chaperone Therapeutics, Inc.
Inventor： Dennis J. Thiele , Daniel W. Neef , Jose S. Mendoza
IPC: C07D231/10 , C07D409/04 , A61K31/415 , A61K31/4155 , A61K31/426 , A61K45/06 , C07D231/40 , C07D277/42 , C07D277/60 , C07K14/47 , C07C211/01 , C07D231/38 , C07D277/38 , C07D405/14 , C07D413/12 , C07C211/29 , C07D277/46
CPC classification number: C07D231/40 , A61K31/415 , A61K31/4155 , A61K31/426 , A61K45/06 , C07C211/01 , C07C211/29 , C07D231/38 , C07D277/38 , C07D277/42 , C07D277/46 , C07D277/60 , C07D405/14 , C07D409/04 , C07D413/12 , C07K14/47 , A61K2300/00
Abstract: The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.
-
5.发明申请公开(公告)号：US20170000768A1
公开(公告)日：2017-01-05
申请号：US15269584
申请日：2016-09-19
Applicant: Duke University , Chaperone Therapeutics, Inc.
Inventor： Dennis J. Thiele , Daniel W. Neef , Jose S. Mendoza
IPC: A61K31/415 , A61K31/426 , A61K31/4155
CPC classification number: C07D231/40 , A61K31/415 , A61K31/4155 , A61K31/426 , A61K45/06 , C07C211/01 , C07C211/29 , C07D231/38 , C07D277/38 , C07D277/42 , C07D277/46 , C07D277/60 , C07D405/14 , C07D409/04 , C07D413/12 , C07K14/47 , A61K2300/00
Abstract: The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.
Abstract translation: 本发明涉及HSF活化化合物，其发现方法及其研究和治疗用途，以及其药学上可接受的盐，溶剂合物，螯合物，非共价复合物，前药，混合物（包括R和S对映体形式和外消旋 其混合物）及其药物制剂。 特别地，本发明提供能够促进HSF1同源三聚化的化合物，以及使用这些化合物作为治疗剂来治疗与不规则HSF1活性相关的许多病症的方法。
-
Patent Agency Ranking
公开(公告)号：US20160221958A1
公开(公告)日：2016-08-04
申请号：US15131938
申请日：2016-04-18
Applicant: DUKE UNIVERSITY , CHAPERONE THERAPEUTICS, INC
Inventor： Dennis J. Thiele , Daniel W. Neef , Jose Serafin Mendoza
IPC: C07D231/40 , C07D409/04 , C07C211/29 , C07D277/46 , C07D277/60 , C07D413/12 , C07D405/14 , C07D277/42
CPC classification number: C07D231/40 , A61K31/415 , A61K31/4155 , A61K31/426 , A61K45/06 , C07C211/01 , C07C211/29 , C07D231/38 , C07D277/38 , C07D277/42 , C07D277/46 , C07D277/60 , C07D405/14 , C07D409/04 , C07D413/12 , C07K14/47 , A61K2300/00
Abstract: The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.
Abstract translation: 本发明涉及HSF活化化合物，其发现方法及其研究和治疗用途，以及其药学上可接受的盐，溶剂合物，螯合物，非共价复合物，前药，混合物（包括R和S对映体形式和外消旋 其混合物）及其药物制剂。 特别地，本发明提供能够促进HSF1同源三聚化的化合物，以及使用这些化合物作为治疗剂来治疗与不规则HSF1活性相关的许多病症的方法。
-
公开(公告)号：US12098117B2
公开(公告)日：2024-09-24
申请号：US17312858
申请日：2019-12-11
Applicant: DUKE UNIVERSITY
Inventor： Dennis J. Thiele , Bushu Dong , Alexander M. Jaeger , Philip F. Hughes , Timothy Haystead , Jiyong Hong
IPC: C07C275/30 , A61P35/00 , C07C211/40 , C07C255/60 , C07C275/28 , C07C275/34 , C07C275/40 , C07C275/42 , C07C279/18 , C07C279/28 , C07C281/06 , C07C311/46 , C07C317/36 , C07C317/42 , C07D213/40 , C07D213/75 , C07D223/04 , C07D229/02 , C07D231/56 , C07D233/64 , C07D241/24 , C07D249/14 , C07D271/12 , C07D285/10 , C07D317/66 , C07D333/20 , C07D333/36 , C07D333/72 , C07D405/04 , C07D405/12 , C07D417/12
CPC classification number: C07C275/30 , A61P35/00 , C07C211/40 , C07C255/60 , C07C275/28 , C07C275/34 , C07C275/40 , C07C275/42 , C07C279/18 , C07C279/28 , C07C281/06 , C07C311/46 , C07C317/36 , C07C317/42 , C07D213/40 , C07D213/75 , C07D223/04 , C07D229/02 , C07D231/56 , C07D233/64 , C07D241/24 , C07D249/14 , C07D271/12 , C07D285/10 , C07D317/66 , C07D333/20 , C07D333/36 , C07D333/72 , C07D405/04 , C07D405/12 , C07D417/12
Abstract: This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.
-
公开(公告)号：US20220106265A1
公开(公告)日：2022-04-07
申请号：US17312858
申请日：2019-12-11
Applicant: DUKE UNIVERSITY
Inventor： Dennis J. Thiele , Bushu Dong , Alexander M. Jaeger , Philip F. Hughes , Timothy Haystead , Jiyong Hong
IPC: C07C275/30 , A61P35/00 , C07D271/12 , C07D233/64 , C07C275/34 , C07D285/10 , C07C311/46 , C07D231/56 , C07D317/66 , C07D333/72 , C07D229/02 , C07C225/20 , C07D213/40 , C07D213/75 , C07D333/20 , C07D417/12 , C07C279/18 , C07C281/06 , C07D241/24 , C07D405/12 , C07D249/14 , C07D333/36 , C07D405/04 , C07D223/04 , C07C317/36
Abstract: This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.
-
公开(公告)号：US20240317727A1
公开(公告)日：2024-09-26
申请号：US18662751
申请日：2024-05-13
Applicant: Duke University , Sisu Pharma, Inc.
Inventor： Dennis J. Thiele , Sean O'Brien
IPC: C07D413/12 , C07C275/40 , C07C311/08 , C07C317/14 , C07D257/04 , C07D265/30 , C07D285/14 , C07D307/81 , C07D333/66 , C07D333/76 , C07D335/06 , C07D409/12
CPC classification number: C07D413/12 , C07C275/40 , C07C311/08 , C07C317/14 , C07D257/04 , C07D265/30 , C07D285/14 , C07D307/81 , C07D333/66 , C07D333/76 , C07D335/06 , C07D409/12 , C07C2601/16
Abstract: This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.
-
10.发明授权公开(公告)号：US09333213B2
公开(公告)日：2016-05-10
申请号：US14213207
申请日：2014-03-14
Applicant: Duke University
Inventor： Katherine J. Franz , Dennis J. Thiele , Marian Helsel , Richard Festa
IPC: A61K31/435 , A61K31/69
CPC classification number: A61K31/69 , A61K31/40 , A61K31/435 , Y02A50/473
Abstract: The present disclosure provides methods of treating (including ameliorating and/or preventing) pathogenic infections by administering a therapeutically effective amount of a prochelator. The present disclosure further provides pharmaceutical compositions and a kit comprising the prochelator therein.
Abstract translation: 本公开提供了通过施用治疗有效量的制成者来治疗（包括改善和/或预防）致病性感染的方法。 本公开进一步提供药物组合物和其中包含其中的代理商的试剂盒。
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.022 seconds)
